

# Mei Kim Ang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8717418/publications.pdf>

Version: 2024-02-01

30  
papers

957  
citations

687363

13  
h-index

552781

26  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1788  
citing authors

#	ARTICLE	IF	CITATIONS
1	Concurrent Chemo-Radiation With or Without Induction Gemcitabine, Carboplatin, and Paclitaxel: A Randomized, Phase 2/3 Trial in Locally Advanced Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 952-960.	0.8	197
2	Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. <i>Cancer</i> , 2015, 121, 1599-1607.	4.1	163
3	Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. <i>Nature Medicine</i> , 2017, 23, 1167-1175.	30.7	141
4	Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 139, 207-215.	2.0	79
5	Advances in systemic treatment for nasopharyngeal carcinoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 21-21.	1.2	69
6	EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, 529-538.	1.1	57
7	Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1928-1934.	1.1	30
8	Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2015, 10, e0123587.	2.5	30
9	Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2131892.	5.9	25
10	A Decade of Never-smokers Among Lung Cancer Patients: Increasing Trend and Improved Survival. <i>Clinical Lung Cancer</i> , 2018, 19, e539-e550.	2.6	21
11	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. <i>BMC Cancer</i> , 2018, 18, 1198.	2.6	18
12	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). <i>PLoS ONE</i> , 2019, 14, e0224665.	2.5	17
13	Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 88, 289-296.	2.0	16
14	Imaging features of renal complications after crizotinib treatment for non-small-cell lung cancer: a case report. <i>Radiology Case Reports</i> , 2016, 11, 245-247.	0.6	14
15	Outcomes and Prognostic Factors of Radiation-Induced and De Novo Head and Neck Squamous Cell Carcinomas. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 154, 880-887.	1.9	11
16	A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancer. <i>Oncotarget</i> , 2017, 8, 79556-79566.	1.8	11
17	Metronomic chemotherapy: A relook at its basis and rationale. <i>Cancer Letters</i> , 2017, 388, 328-333.	7.2	10
18	Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1650-1659.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Germline hemizygous deletion of CDKN2A/CDKN2B locus in a patient presenting with Li-Fraumeni syndrome. <i>Npj Genomic Medicine</i> , 2016, 1, 16015.	3.8	9
20	Phase II study of nimotuzumab (TheraCim®/hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 1641-1651.	2.0	7
21	Pairing a prognostic target with potential therapeutic strategy for head and neck cancer. <i>Oral Oncology</i> , 2020, 111, 105035.	1.5	6
22	A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2008, 1, 159-165.	0.9	4
23	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study: An Asian Tertiary Cancer Center Experience. <i>JCO Precision Oncology</i> , 2021, 5, 859-875.	3.0	4
24	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 70-80.	0.8	3
25	Twenty-five years of <i>Respirology</i> : Advances in lung cancer. <i>Respirology</i> , 2020, 25, 26-31.	2.3	2
26	Relationship between tumor response with outcomes in EGFR mutation positive (M+) non-small cell lung cancer (NSCLC) treated with tyrosine-kinase inhibitors (TKI).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19101-e19101.	1.6	0
27	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). , 2019, 14, e0224665.		0
28	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). , 2019, 14, e0224665.		0
29	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). , 2019, 14, e0224665.		0
30	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). , 2019, 14, e0224665.		0